STOCK TITAN

PharmaCyte Biotech, Inc. - $PMCB STOCK NEWS

Welcome to our dedicated page for PharmaCyte Biotech news (Ticker: $PMCB), a resource for investors and traders seeking the latest updates and insights on PharmaCyte Biotech stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect PharmaCyte Biotech's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of PharmaCyte Biotech's position in the market.

Rhea-AI Summary
PharmaCyte Biotech, Inc. (Nasdaq: PMCB) announces a $5 million investment in Femasys, Inc. (Nasdaq:FEMY), marking an expansion of its corporate strategy to create additional shareholder value. The investment aims to utilize PharmaCyte's significant cash position and contribute to Femasys' development of innovative women's health solutions, including a non-surgical, in-office permanent birth control method.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.6%
Tags
-
Rhea-AI Summary
PharmaCyte Biotech provides an update on its Cell-in-a-Box technology and plans to request a meeting with the FDA for further development guidance. The company is reviewing potential opportunities for its $74.6 million cash position. The technology offers targeted delivery of cancer-killing drugs with minimized side effects.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.44%
Tags
none
-
Rhea-AI Summary
PharmaCyte Biotech completes tender offer, acquiring 8,085,879 shares of common stock for $26,279,106.75.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.66%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
12.77%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.69%
Tags
buyback
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.23%
Tags
management
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.66%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.42%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.42%
Tags
management
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.35%
Tags
none
PharmaCyte Biotech, Inc.

Nasdaq:PMCB

PMCB Rankings

PMCB Stock Data

18.26M
8.07M
8.12%
15.05%
0.54%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
United States of America
LAGUNA HILLS

About PMCB

pharmacyte biotech, inc., a clinical stage biotechnology company, focuses on developing and commercializing cellular therapies for cancer and diabetes in the united states. its cellular therapies are developed based on cell-in-a-box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types of cancer, including advanced and inoperable non-metastatic pancreatic cancer, as well as diabetes. the company is developing therapies for pancreatic and other solid cancerous tumors involving the encapsulation of live cells placed in the body to enable the activation of cancer-killing drugs to the source of the cancer. it is also developing a therapy for type 1 diabetes and insulin-dependent type 2 diabetes; and therapies for cancer based on the constituents of the cannabis plant. pharmacyte biotech, inc. has a research agreement with the university of technology, sydney to create a version of melligen cells to treat diabetes; and a research agreeme